In January, when Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology ...

Amgen’s long-awaited Humira biosimilar, Amjevita, has finally hit the market. After years of sitting on the biosimilar, which won an FDA approval in 2016, Amgen is ready to make waves.

Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited discounts for its biosimilar version of Humira — the world’s best-selling medicine — and the ...

With at least six others behind it, Amgen Inc.’s Amjevita is leading a 2023 U.S. biosimilars charge to challenge the all-time biggest-selling drug, Humira (adalimumab), from Abbvie Inc. Amjevita hit ...

Jan 31 (Reuters) - Amgen Inc (AMGN.O), opens new tab said on Tuesday it launched a biosimilar version of AbbVie Inc's (ABBV.N), opens new tab big selling arthritis treatment, the first such ...

Drugmaker Amgen on Tuesday launched a biosimilar to the widely-prescribed Humira, giving consumers an alternative to the world's top-selling rheumatoid arthritis drug. The new drug, Amjevita, will be ...

After 20 years and $200 billion in revenue, Humira — an injectable treatment for rheumatoid arthritis and several other autoimmune conditions — has lost its monopoly. Early Tuesday morning, California ...

Drugmakers AbbVie Inc.ABBV0.48%increase; green up pointing triangle and Amgen Inc. AMGN 0.75%increase; green up pointing triangle reached a patent-dispute settlement requiring Amgen to wait until 2023 ...